Yves Pommier

Molecular Biology · 2000–2016

A researcher in the Science corpus: 16 papers; trusts 14 researchers and is trusted by 12 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 151 citations into it; #3,080 of 17,773 by trust here, #3,494 by citations
• Oncology — 94 citations into it; #168 of 1,698 by trust here, #679 by citations
• Cancer Research — 30 citations into it
• Cell Biology — 7 citations into it
• Pulmonary and Respiratory Medicine — 5 citations into it

Whom Yves Pommier trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Kastan
2. Mark J. O'Connor
3. James J. Champoux
4. J. Nitiss
5. J. Bartek
6. S. Lapenna
7. James C. Wang
8. N. Curtin
9. Alan Ashworth
10. Elisabetta Leo

Who trusts Yves Pommier overall

1. Mark J. O'Connor
2. Nicolas Le Novère
3. G. Barrera
4. Elisabetta Leo
5. J. D. de Bono
6. Eduardo Vilar
7. Hongliang Zhang
8. C. Lord
9. Phatsapong Yingchoncharoen
10. Hezekiel M. Kumalo

Papers from Yves Pommier's perspective

Ordered by how strongly the researchers Yves Pommier trusts endorse each paper. Same corpus, a different order for every researcher.

1. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks (Cell)
2. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase (Nature)
3. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (Proceedings of the National Academy of Sciences of the United States of America)
4. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. (The Lancet Oncology)
5. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (EMBO Molecular Medicine)
6. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer (New England Journal of Medicine)
7. DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs (Chemistry and Biology)
8. Cell-cycle checkpoints and cancer (Nature)
9. DNA repair dysregulation from cancer driver to therapeutic target (Nature Reviews. Cancer)
10. MDC1 is a mediator of the mammalian DNA damage checkpoint (Nature)

Their papers

• CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set (2012) — 783 citations
• A gene expression database for the molecular pharmacology of cancer (2000) — 1,467 citations
• DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs (2010) — 1,790 citations
• Initiation of DNA Fragmentation during Apoptosis Induces Phosphorylation of H2AX Histone at Serine 139* (2000) — 734 citations
• Topoisomerase I inhibitors: camptothecins and beyond (2006) — 2,121 citations
• γH2AX and cancer (2008) — 1,308 citations
• Drugging Topoisomerases: Lessons and Challenges (2013) — 771 citations
• Differential trapping of PARP1 and PARP2 by clinical PARP inhibitors (2012) — 1,883 citations
• Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib (2013) — 703 citations
• DNA Topoisomerase I Inhibitors: Chemistry, Biology and Interfacial Inhibition (2009) — 665 citations
• Integrase inhibitors to treat HIV/Aids (2005) — 686 citations
• Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks (2004) — 604 citations
• Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action (2016) — 665 citations
• Roles of eukaryotic topoisomerases in transcription, replication and genomic stability (2016) — 847 citations
• CellMiner: a relational database and query tool for the NCI-60 cancer cell lines (2009) — 354 citations
• Phosphorylation of BLM, Dissociation from Topoisomerase IIIα, and Colocalization with γ-H2AX after Topoisomerase I-Induced Replication Damage (2005) — 85 citations